Janus Kinase Inhibitor

The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, according to data published in The Journal of Rheumatology.

The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.

A long-term safety analysis of filgotinib for moderate-to-severe rheumatoid arthritis demonstrated potential dose-dependent risks for herpes zoster, malignancies and all-cause mortality in patients aged 65 and older, according to data.

In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.

WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.

Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results.

SAN DIEGO — In this Healio video perspective here at the American Academy of Dermatology, Brett King, MD, PhD, FAAD, discusses how new Janus kinase inhibitors have changed the paradigm of alopecia areata treatment.